Retrieved on:
Wednesday, April 10, 2024
CE,
Asos,
Drug discovery,
Central nervous system,
Patient,
Ophthalmology,
RNA,
Research,
CBO,
Protein,
Drug development,
Medical device EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
Key Points:
- EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
The issuer is solely responsible for the content of this announcement.
- Dallas, TX, USA and Martinsried, Germany, March 20, 2024 – Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
- “Collaborating with Secarna allows us to develop an innovative implant that has the potential to significantly change the way disease-modifying ASO therapies are administered,” said Cyonna Holmes, Global Business Strategy Leader for Ophthalmology and RNA at Celanese.
- “We are looking forward to partnering with Celanese to combine our industry-leading ASO platform with their VitalDose® drug delivery technology,” said Konstantin Petropoulos, CBO of Secarna Pharmaceuticals.
Retrieved on:
Wednesday, March 20, 2024
Research,
General Health,
Pharmaceutical,
Oncology,
Data Management,
Technology,
Infectious Diseases,
Science,
Chemicals,
Plastics,
Biotechnology,
Manufacturing,
Health,
CE,
Asos,
Drug discovery,
Central nervous system,
Patient,
Corporation,
Ophthalmology,
RNA,
CBO,
Protein,
Drug development,
Medical device Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
Key Points:
- Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
- “Collaborating with Secarna allows us to develop an innovative implant that has the potential to significantly change the way disease-modifying ASO therapies are administered,” said Cyonna Holmes, global business strategy leader for Ophthalmology and RNA at Celanese.
- With several high value and innovative programs, Secarna has validated its platform in various indications such as cardiometabolic, immune-oncology, fibrotic/inflammatory diseases and the central nervous system.
- “We are looking forward to partnering with Celanese to combine our industry-leading ASO platform with their VitalDose® drug delivery technology,” said Konstantin Petropoulos, CBO of Secarna Pharmaceuticals.
Retrieved on:
Tuesday, November 7, 2023
Survival,
Plasma,
NRP1,
ASO,
Neuropilin 1,
Conference,
LNA,
Asos,
Doctor of Philosophy,
Oligonucleotide,
Poster,
Mouse,
SITC,
Immunotherapy,
Spatial analysis,
Animal,
Tumor microenvironment,
Cancer,
Gene expression,
The Society,
Fine chemical,
Vaccine The data were presented at The Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting & Pre-Conference Programs (SITC 2023) in San Diego, which took place November 1 – 5, 2023.
Key Points:
- The data were presented at The Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting & Pre-Conference Programs (SITC 2023) in San Diego, which took place November 1 – 5, 2023.
- As our LNA-modified ASOs potently reduce the expression of NRP1, all of these functions will be suppressed simultaneously.
- Using the Company’s in-house Oligofyer™ system, Secarna designed locked nucleic acid (LNA) modified ASOs specifically targeting NRP1.
- Secarna is currently planning studies to further delineate the proposed antitumor mechanisms of the NRP1 ASOs by spatial analysis of the tumor microenvironment.
Retrieved on:
Thursday, October 26, 2023
Knowledge,
OTS,
ASO,
LNA,
Asos,
Doctor of Philosophy,
IDO1,
Oligonucleotide,
TLR9,
Kinetics,
Patient,
Infection,
Fine chemical The two posters were presented this week, at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
Key Points:
- The two posters were presented this week, at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
- The poster 201: Characterization of immunostimulatory potential of LNA-modified antisense oligonucleotides was presented by Irene Riera Tur, PhD.
- It could be shown that, among others, LNA-modified ASOs actually can induce activation of the human TLR9 pathway and downstream signaling.
- “These data confirm our previous studies and convince us that we are on the right path to fully exploit the potential of ASOs.
Retrieved on:
Tuesday, October 17, 2023
Oligonucleotide,
TLR9,
OTS,
Kinetics,
LNA,
ASO,
Asos,
Patient,
Poster,
Infection,
Fine chemical Munich/Martinsried, Germany, October 17, 2023 – Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAplus platform, will present data showcasing the continuous progress and innovation generated by the Company’s cutting-edge LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society (OTS).
Key Points:
- Munich/Martinsried, Germany, October 17, 2023 – Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAplus platform, will present data showcasing the continuous progress and innovation generated by the Company’s cutting-edge LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society (OTS).
- The meeting will be held October 22-25, 2023 in Barcelona, Spain.
- This pathway, which has the physiological function to rapidly recognize infections and initiate an early immune response, can be activated by therapeutic oligonucleotides.
- TLR9 activity of oligonucleotides depends on their sequence, but chemical modifications, such as LNA modification, also impact their immunostimulatory potential.
Asos,
Asthma,
Central nervous system,
University,
Chronic kidney disease,
Arthritis,
Fever,
NOMID,
FCAS,
Survival,
Autoinflammatory diseases,
NLRP3,
Quality of life,
MWS,
University of California, San Diego Performance-Based Skills Assessment,
Inflammation,
Life expectancy,
CAPS,
Journal of Immunology,
Inflammatory bowel disease,
Hyperkinesia,
Skin,
Journal,
Patient,
NLR,
Fatty liver disease,
ASO,
Weight gain,
Fine chemical,
Vaccine,
Pharmaceutical industry Using its proprietary Oligofyer™ bioinformatics system, Secarna designed LNAplus™ ASOs to specifically suppress the expression of the NLR family pyrin domain containing 3 (NLRP3), the central component of the inflammasome pathway.
Key Points:
- Using its proprietary Oligofyer™ bioinformatics system, Secarna designed LNAplus™ ASOs to specifically suppress the expression of the NLR family pyrin domain containing 3 (NLRP3), the central component of the inflammasome pathway.
- CAPS are a spectrum of autoinflammatory diseases caused by activating mutations in the NLRP3 gene.
- The activity of NLRP3-ASO was tested in an in vivo NOMID disease model; NOMID is the most severe form of CAPS.
- After systemic ASO treatment, life expectancy was significantly increased, with weight gains and reductions in the severity of skin lesions, showing an overall reduction in systemic inflammation.
University of Geneva,
Asos,
DNA,
ICIS,
Human,
University,
Therapy,
ICI,
University of Basel,
Neoplasm,
DC,
TLR9,
Immunity,
DC3 Music Group,
Journal,
Patient,
Pathology,
Mouse,
ASO,
Immunology,
Immunotherapy,
B cell,
PD-L1,
Toll-like receptor 9,
Vaccine,
Pharmaceutical industry,
Cancer TLR9 signaling is an important innate immune pathway that is relevant as a first-line defense mechanism against pathogens.
Key Points:
- TLR9 signaling is an important innate immune pathway that is relevant as a first-line defense mechanism against pathogens.
- A drawback to this approach is that the TLR9 –mediated immune response is blunted by immediate upregulation of immune checkpoints such as PD-L1.
- The combined downregulation of PD-L1 expression in a single-molecule approach resulted in exceptional antitumor activity in different tumor models.
- “Our recently published data demonstrate the potential therapeutic effect of simultaneously targeting TLR9 and PD-L1, key modulators of the innate and adaptive immune system, respectively, with a bimodal ASO.
EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
Key Points:
- EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
The issuer is solely responsible for the content of this announcement.
- Munich/Martinsried, Germany, March 27, 2023 – Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, and SciNeuro Pharmaceuticals (“SciNeuro”), a leader in the discovery and development of innovative therapeutics for the treatment of neurological diseases, today announced the signature of a multi-target research and option agreement.
- Within the collaboration, the companies will work together to generate novel ASO therapies directed at targets that play a critical role in diseases of the Central Nervous System.
- “We are looking forward to collaborating with SciNeuro and to combine our industry-leading antisense oligonucleotide platform LNAplus™ with SciNeuro’s strong expertise and capabilities in the field of CNS diseases,” said Alexander Gebauer, M.D., Ph.D., CEO of Secarna Pharmaceuticals.
